交易信息汇总资金流向 9月10日主力资金净流出470.2万元；游资资金净流出216.91万元；散户资金净流入687.11万元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 董秘： 投资者，您好！感谢您对公司的关注，不同机构在行业分类时侧重点不同导致分类出现差异， 公司在证监会行业信息里划分为医药制造业，谢谢。 投资者： 为什么同样是三甲医院，金陵药业旗下的宿迁医院，近年来营收停滞，利润持续减少，而国 际医学旗下的西安高新医院，营收和利润持续增长呢？请管理层给广大股东解释一下！ 董秘： 投资者，您好！感谢您对公司的关注，相关信息请参考公司在指定媒体披露的公告，谢谢！ 当日关注点 来自交易信息汇总：9月10日主力资金净流出470.2万元，散户资金净流入687.11万元。 截至2025年9月10日收盘，金陵药业(000919)报收于7.2元，下跌0.28%，换手率1.15%，成交量6.79万 手，成交额4891.16万元。 董秘最新回复 投资者： 金陵药业现在医疗服务板块的营收占比超过50%，但是同花顺是显示公司还属于化学制药行 业， ...

截至2月10日，金陵药业股东户数3.71万，人均流通股1.59万股。 2024年1月-9月，金陵药业实现营业收入22.2亿元，同比增长5.51%；归属净利润7136.87万元，同比减少 26.88%。 8月7日，金陵药业盘中上涨5.48%，截至09:33，报7.51元/股，成交4628.2万元，换手率1.08%，总市值 46.84亿元。 资料显示，金陵药业股份有限公司位于南京经济技术开发区新港大道58号，公司主要业务包括医药和医 康养两个产业平台，医药版块拥有近百个品规的中西药品的生产能力，医康养版块控股三家综合性医院 和一家医康养一体化项目公司。公司于1999年在深圳证券交易所发行8000万股A股股票并上市，现控股 股东为南京新工投资集团有限责任公司。 ...

规格：150mg、200mg 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 金陵药业股份有限公司（以下简称"公司"）于2025年6月24日披露了《关于分公司收到噁拉戈利片受理 通知书的公告》（公告编号：2025-042），公司分公司金陵药业股份有限公司南京金陵制药厂（以下简 称"金陵制药厂"）收到国家药品监督管理局下发的噁拉戈利片临床试验申请受理通知书。近日，金陵制 药厂收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准噁拉戈利片开展Ⅲ期临床 研究。现将相关情况公告如下： 一、《药物临床试验批准通知书》的主要内容 产品名称：噁拉戈利片 注册分类：化学药品3类 申请事项：临床试验申请 受理号：CYHL2500117、CYHL2500118 特此公告。 金陵药业股份有限公司 董事会 申请的适应症：用于治疗与子宫内膜异位症相关的中度至重度疼痛。 申请人：金陵药业股份有限公司南京金陵制药厂 审查结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年6月20日受理的噁拉戈利 片临床试验申请符 ...

Key Points - Tianpu Co., Ltd. announced a suspension of trading for stock verification due to multiple instances of abnormal trading fluctuations from August 22 to September 3, with a reminder for investors about market risks [1] - China Shipbuilding Industry Corporation announced a share exchange ratio of 1:0.1339 for the merger with China Shipbuilding, with the stock ceasing to be listed from September 5, 2025 [2] - Chengdu Huamei reported that its 40G high-precision RF ADC chip is still in the trial production stage and has not achieved mass sales, indicating market demand uncertainty [2] - Taihe Technology's sulfide solid electrolyte project is currently in the trial production phase and has not generated sales revenue [3] - Robotech signed a contract worth approximately €946.50 million for fully automated silicon photonic packaging equipment, expected to positively impact the company's future performance [4] - Wento Holdings reported that its cinema and gaming businesses are still in the recovery phase post-restructuring, with potential uncertainties in future operations [5] - Xibu Muye's fresh milk production increased by 4.8% month-on-month in August [6] - China Shipbuilding announced the implementation of a share exchange merger with China Heavy Industry [6] - Gansu Energy plans to invest CNY 40.89 billion in a wind-solar integrated project [6] - Xinhua Medical's endoscope cleaning workstation received a Class II medical device registration certificate [6]

（文章来源：证券日报） 证券日报网讯 9月3日晚间，金陵药业发布公告称，公司于2025年6月24日披露了《关于分公司收到噁拉 戈利片受理通知书的公告》，公司分公司金陵药业股份有限公司南京金陵制药厂（简称"金陵制药厂"） 收到国家药品监督管理局下发的噁拉戈利片临床试验申请受理通知书。近日，金陵制药厂收到国家药品 监督管理局核准签发的《药物临床试验批准通知书》，批准噁拉戈利片开展Ⅲ期临床研究。 ...

Core Viewpoint - Jinling Pharmaceutical has received approval for the Phase III clinical trial of Orelagol, a GnRH antagonist for treating moderate to severe pain associated with endometriosis, indicating a significant step in its product development pipeline [1] Group 1: Company Overview - Jinling Pharmaceutical's main business includes pharmaceutical and medical device manufacturing, as well as health care services [1] - The company’s product range covers cardiovascular, iron supplements, gastrointestinal medications, and oncology supportive drugs [1] - The company has a strong competitive advantage in the iron supplement market with its key product, Succinic Acid Iron Tablets [1] Group 2: Recent Financial Performance - In the first half of 2025, the company reported revenue of 1.6 billion yuan, a decrease of 6.6% year-on-year [1] - The net profit attributable to shareholders was 48.33 million yuan, down 14.08% year-on-year [1] - The net profit excluding non-recurring items was 35.51 million yuan, reflecting a decline of 21.6% year-on-year [1] Group 3: Business Strategy and Innovation - The company emphasizes the synergy between its pharmaceutical and health care platforms to support stable and high-quality development [2] - The pharmaceutical segment plays a crucial role, focusing on growth stabilization, cost reduction, structural adjustment, and capacity enhancement [2] - R&D investment increased by 20.51% year-on-year to 45.34 million yuan, with progress in product development and patent applications [2]

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Group 1 - The company, Jinling Pharmaceutical, announced on September 3 that its subsidiary, Nanjing Jinling Pharmaceutical Factory, received a clinical trial application acceptance notice for Olaragol tablets from the National Medical Products Administration [1] - The company has also received the approval notice for the clinical trial, allowing the commencement of Phase III clinical research for Olaragol tablets [1]

Core Viewpoint - Jinling Pharmaceutical (000919.SZ) has received approval from the National Medical Products Administration for the clinical trial of Orelizumab tablets, marking a significant step in its development pipeline [1] Group 1: Company Developments - Jinling Pharmaceutical's subsidiary, Nanjing Jinling Pharmaceutical Factory, has been granted a clinical trial application acceptance notice for Orelizumab tablets [1] - The company has also received the Drug Clinical Trial Approval Notice, allowing the commencement of Phase III clinical research for Orelizumab tablets [1] Group 2: Product Information - Orelizumab is an oral GnRH antagonist primarily used for treating moderate to severe pain associated with endometriosis [1] - The product is included in the National "Second Batch of Encouraged Generic Drug List" [1]

Core Viewpoint - Jinling Pharmaceutical (000919) has received approval from the National Medical Products Administration for the clinical trial of Olaragoli tablets, which are intended for the treatment of moderate to severe pain associated with endometriosis [1] Company Summary - Jinling Pharmaceutical's subsidiary, Jinling Pharmaceutical Factory, has been granted a Clinical Trial Approval Notice for Olaragoli tablets [1] - The clinical research will be conducted in Phase III, indicating a significant step towards potential market introduction [1] Industry Summary - The approval of Olaragoli tablets highlights ongoing advancements in the pharmaceutical industry, particularly in addressing women's health issues such as endometriosis [1]